Literature DB >> 19237683

A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial.

Ross D Feldman1, Guang Y Zou, Margaret K Vandervoort, Cindy J Wong, Sigrid A E Nelson, Brian G Feagan.   

Abstract

Notwithstanding the availability of antihypertensive drugs and practice guidelines, blood pressure control remains suboptimal. The complexity of current treatment guidelines may contribute to this problem. To determine whether a simplified treatment algorithm is more effective than guideline-based management, we studied 45 family practices in southwestern Ontario, Canada, using a cluster randomization trial comparing the simplified treatment algorithm with the Canadian Hypertension Education Program guidelines. The simplified treatment algorithm consisted of the following: (1) initial therapy with a low-dose angiotensin-converting enzyme inhibitor/diuretic or angiotensin receptor blocker/diuretic combination; (2) up-titration of combination therapy to the highest dose; (3) addition of a calcium channel blocker and up-titration; and (4) addition of a non-first-line antihypertensive agent. The proportion of patients treated to target blood pressure (systolic blood pressure <140 mm Hg and diastolic blood pressure <90 mm Hg for patients without diabetes mellitus or systolic blood pressure <130 mm Hg and diastolic blood pressure <80 mm Hg for diabetic patients) at 6 months was analyzed at the practice level. The proportion of patients achieving target was significantly higher in the intervention group (64.7% versus 52.7%; absolute difference: 12.0%; 95% CI: 1.5% to 22.4%; P=0.026). Multivariate analysis of patient-level data showed that assignment to the intervention arm increased the chance of reaching the target by 20% (P=0.028), when adjusted for other covariates. In conclusion, the Simplified Treatment Intervention to Control Hypertension Study indicates that a simplified antihypertensive algorithm using initial low-dose fixed-dose combination therapy is superior to guideline-based practice for the management of hypertension.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19237683     DOI: 10.1161/HYPERTENSIONAHA.108.123455

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  68 in total

Review 1.  Should two-drug initial therapy for hypertension be recommended for all patients?

Authors:  Jennifer B Cowart; Addison A Taylor
Journal:  Curr Hypertens Rep       Date:  2012-08       Impact factor: 5.369

2.  A STITCH saves time and lowers blood pressure.

Authors:  Suzanne Oparil
Journal:  Curr Hypertens Rep       Date:  2010-06       Impact factor: 5.369

3.  Discord from ACCORD?

Authors:  Alan B Weder
Journal:  Curr Hypertens Rep       Date:  2011-02       Impact factor: 5.369

4.  Combination therapy as initial treatment for newly diagnosed hypertension.

Authors:  James B Byrd; Chan Zeng; Heather M Tavel; David J Magid; Patrick J O'Connor; Karen L Margolis; Joe V Selby; P Michael Ho
Journal:  Am Heart J       Date:  2011-07-18       Impact factor: 4.749

5.  Association of Low-Dose Triple Combination Therapy With Therapeutic Inertia and Prescribing Patterns in Patients With Hypertension: A Secondary Analysis of the TRIUMPH Trial.

Authors:  Nelson Wang; Abdul Salam; Ruth Webster; Asita de Silva; Rama Guggilla; Sandrine Stepien; Jayanthi Mysore; Laurent Billot; Stephen Jan; Pallab K Maulik; Nitish Naik; Vanessa Selak; Simon Thom; Dorairaj Prabhakaran; Anushka Patel; Anthony Rodgers
Journal:  JAMA Cardiol       Date:  2020-11-01       Impact factor: 14.676

6.  Hypertension Canada's 2017 guidelines for diagnosis, risk assessment, prevention and treatment of hypertension in adults for pharmacists: An update.

Authors:  Sarah A Lamb; Yazid N Al Hamarneh; Sherilyn K D Houle; Alexander A Leung; Ross T Tsuyuki
Journal:  Can Pharm J (Ott)       Date:  2017-11-29

Review 7.  How well do guidelines incorporate evidence on patient preferences?

Authors:  Christopher A K Y Chong; Ing-je Chen; Gary Naglie; Murray D Krahn
Journal:  J Gen Intern Med       Date:  2009-04-23       Impact factor: 5.128

8.  Improved Identification and Antihypertension Pharmacotherapy in Cardiorenal Metabolic Syndrome: Focus on Racial/Ethnic Minorities, Olmesartan Medoxomil, and Combination Therapy.

Authors:  Keith C Ferdinand
Journal:  Cardiorenal Med       Date:  2012-10-26       Impact factor: 2.041

9.  Impact of rheumatoid arthritis on receiving a diagnosis of hypertension among patients with regular primary care.

Authors:  Christie M Bartels; Heather Johnson; Katya Voelker; Carolyn Thorpe; Patrick McBride; Elizabeth A Jacobs; Nancy Pandhi; Maureen Smith
Journal:  Arthritis Care Res (Hoboken)       Date:  2014-09       Impact factor: 4.794

Review 10.  Resistant Hypertension: Time to Consider the Best Fifth Anti-Hypertensive Treatment.

Authors:  Andrea Pio-Abreu; Luciano F Drager
Journal:  Curr Hypertens Rep       Date:  2018-06-16       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.